Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.

about

Use of FLT3 inhibitors in acute myeloid leukemia remission induction or salvage therapy: systematic review and meta-analysis

P2860

Q58781994-B5DD3248-9927-4B05-9F66-29FFA3DC8BBA

P2860

Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.

Item

http://www.wikidata.org/entity/Q38913785

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.

@en

type

Item

label

Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.

@en

prefLabel

Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.

@en

P1476

Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.

@en

P2093

A Elizabeth Guzmán-Hernández

http://www.w3.org/2001/XMLSchema#string

Carlos Best-Aguilera

http://www.w3.org/2001/XMLSchema#string

O Rodrigo Gómez-Vázquez

http://www.w3.org/2001/XMLSchema#string

R Monserrat Rojas-Sotelo

http://www.w3.org/2001/XMLSchema#string

P2860

Midostaurin: an emerging treatment for acute myeloid leukemia patients

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia.

Molecular therapy for acute myeloid leukaemia.

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

P2888

s11912-017-0573-x

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11912-017-0573-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084033419

http://www.w3.org/2001/XMLSchema#string

P698

28283965

http://www.w3.org/2001/XMLSchema#string

Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.

about

P2860

P2860

Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698